These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35115074)

  • 1. Propofol Withdrawal Dyskinesia in a Parkinson's Disease Patient with Levodopa-Induced Dyskinesia.
    Nakajima A; Iwamuro H; Tokugawa J; Odo M; Shimo Y
    Can J Neurol Sci; 2023 Mar; 50(2):322-323. PubMed ID: 35115074
    [No Abstract]   [Full Text] [Related]  

  • 2. Adenosine receptors and L-DOPA-induced dyskinesia in Parkinson's disease: potential targets for a new therapeutic approach.
    Blandini F
    Exp Neurol; 2003 Dec; 184(2):556-60. PubMed ID: 14769348
    [No Abstract]   [Full Text] [Related]  

  • 3. Classifying risk factors for dyskinesia in Parkinson's disease.
    Sharma JC; Bachmann CG; Linazasoro G
    Parkinsonism Relat Disord; 2010 Sep; 16(8):490-7. PubMed ID: 20598622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Motor fluctuations and dyskinesia in Parkinson's disease.
    Nutt JG
    Parkinsonism Relat Disord; 2001 Oct; 8(2):101-8. PubMed ID: 11489675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dyskinesias induced by subthalamotomy in Parkinson's disease are unresponsive to amantadine.
    Merello M; Perez-Lloret S; Antico J; Obeso JA
    J Neurol Neurosurg Psychiatry; 2006 Feb; 77(2):172-4. PubMed ID: 16421117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On automated assessment of Levodopa-induced dyskinesia in Parkinson's disease.
    Tsipouras MG; Tzallas AT; Fotiadis DI; Konitsiotis S
    Annu Int Conf IEEE Eng Med Biol Soc; 2011; 2011():2679-82. PubMed ID: 22254893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KH
    Cochrane Database Syst Rev; 2001; (1):CD001517. PubMed ID: 11279719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can therapeutic strategies prevent and manage dyskinesia in Parkinson's disease? An update.
    Leta V; Jenner P; Chaudhuri KR; Antonini A
    Expert Opin Drug Saf; 2019 Dec; 18(12):1203-1218. PubMed ID: 31619083
    [No Abstract]   [Full Text] [Related]  

  • 9. Levodopa-induced dyskinesia: do current clinical trials hold hope for future treatment?
    Alsalmi M; Al-Kassmy J; Kang W; Palayew M; Huot P
    Expert Opin Pharmacother; 2024; 25(1):1-3. PubMed ID: 38116733
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of Subthalamic Deep Brain Stimulation on Levodopa-Induced Dyskinesia in Parkinson's Disease.
    Kim JH; Chang WS; Jung HH; Chang JW
    Yonsei Med J; 2015 Sep; 56(5):1316-21. PubMed ID: 26256974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
    Bezard E; Brotchie JM; Gross CE
    Nat Rev Neurosci; 2001 Aug; 2(8):577-88. PubMed ID: 11484001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CLINICAL TRIAL HIGHLIGHTS - DYSKINESIA.
    McFarthing K; Prakash N; Simuni T
    J Parkinsons Dis; 2019; 9(3):449-465. PubMed ID: 31356217
    [No Abstract]   [Full Text] [Related]  

  • 13. Levodopa-induced belly dancer's dyskinesias in Parkinson's disease: report of one case.
    Carecchio M; Collini A; Comi C; Cantello R; Bhatia KP; Monaco F
    Mov Disord; 2010 Aug; 25(11):1760-2. PubMed ID: 20645401
    [No Abstract]   [Full Text] [Related]  

  • 14. Improvement of dyskinesias with L-dopa infusion in advanced Parkinson's disease.
    Timpka J; Fox T; Fox K; Honig H; Odin P; Martinez-Martin P; Antonini A; Chaudhuri KR
    Acta Neurol Scand; 2016 Jun; 133(6):451-8. PubMed ID: 26358227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study.
    Snow BJ; Macdonald L; Mcauley D; Wallis W
    Clin Neuropharmacol; 2000; 23(2):82-5. PubMed ID: 10803797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resting-state connectivity predicts levodopa-induced dyskinesias in Parkinson's disease.
    Herz DM; Haagensen BN; Nielsen SH; Madsen KH; Løkkegaard A; Siebner HR
    Mov Disord; 2016 Apr; 31(4):521-9. PubMed ID: 26954295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing long-term therapy for Parkinson disease: options for treatment-associated dyskinesia.
    Stacy M; Galbreath A
    Clin Neuropharmacol; 2008; 31(2):120-5. PubMed ID: 18382184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ropinirole for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KH
    Cochrane Database Syst Rev; 2001; (1):CD001516. PubMed ID: 11279718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ropinirole for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KH
    Cochrane Database Syst Rev; 2000; (3):CD001516. PubMed ID: 10908503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rating scales for dyskinesias in Parkinson's disease.
    Goetz CG
    Mov Disord; 1999; 14 Suppl 1():48-53. PubMed ID: 10493403
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.